188 related articles for article (PubMed ID: 26077832)
1. Olanzapine-Induced Reversible Pellagroid Skin Lesion.
Singh LK; Sahu M; Praharaj SK
Curr Drug Saf; 2015; 10(3):251-3. PubMed ID: 26077832
[TBL] [Abstract][Full Text] [Related]
2. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
4. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
6. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
7. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
8. Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent.
Jhirwal OP; Parsad D; Basu D
Int J Dermatol; 2004 Oct; 43(10):778-9. PubMed ID: 15485541
[No Abstract] [Full Text] [Related]
9. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
10. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine-induced vasculitis.
Duggal MK; Singh A; Arunabh ; Lolis JD; Guzik HJ
Am J Geriatr Pharmacother; 2005 Mar; 3(1):21-4. PubMed ID: 16089244
[TBL] [Abstract][Full Text] [Related]
13. Adverse cutaneous reactions to antipsychotics.
Warnock JK; Morris DW
Am J Clin Dermatol; 2002; 3(9):629-36. PubMed ID: 12444805
[TBL] [Abstract][Full Text] [Related]
14. Improvement of dumping syndrome and oversecretion of glucose-dependent insulinotropic polypeptide following a switch from olanzapine to quetiapine in a patient with schizophrenia.
Watanabe A; Fukui N; Suzuki Y; Motegi T; Igeta H; Tsuneyama N; Someya T
Gen Hosp Psychiatry; 2015; 37(4):372.e5-6. PubMed ID: 25835510
[TBL] [Abstract][Full Text] [Related]
15. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
[TBL] [Abstract][Full Text] [Related]
16. EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects.
Amann BL; Pogarell O; Mergl R; Juckel G; Grunze H; Mulert C; Hegerl U
Hum Psychopharmacol; 2003 Dec; 18(8):641-6. PubMed ID: 14696024
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
Sacchetti E; Valsecchi P
Int Clin Psychopharmacol; 2003 Nov; 18(6):357-9. PubMed ID: 14571157
[TBL] [Abstract][Full Text] [Related]
18. Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.
Yu AP; Ben-Hamadi R; Birnbaum HG; Atanasov P; Stensland MD; Philips G
Curr Med Res Opin; 2009 Mar; 25(3):755-64. PubMed ID: 19199435
[TBL] [Abstract][Full Text] [Related]
19. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
20. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
